9:14 AM
 | 
Apr 27, 2018
 |  BC Week In Review  |  Company News  |  Deals

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >